Try
Cogent Biosciences Inc. Common Stock
COGTUnited States
34 filed reports · 359 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
34 reports · Mar 2018 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 26 | 2,777 | Mar 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 8 | 2,503 | Dec 2018 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 10, 2026 | 247 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 151 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 17, 2026 | 634 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 7, 2025 | 184 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 105 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 96 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 25, 2025 | 304 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 107 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 6, 2024 | 88 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 94 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 26, 2024 | 288 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 7, 2023 | 103 | Open |
Financial data
359 concepts · 5,280 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial357 concepts · 5,180 facts · Mar 2017 to Jun 2026
- Fair value asset, transfers between Level 1, Level 2 and Level 3, amount49 · Mar 2017 to Jun 2026
- Allocated share based compensation expense47 · Mar 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents47 · Mar 2017 to Jun 2026
- Comprehensive income net of tax47 · Mar 2017 to Jun 2026
- Costs and expenses47 · Mar 2017 to Jun 2026
- Defined contribution plan employer discretionary contribution amount47 · Mar 2017 to Jun 2026
- Depreciation and amortization47 · Mar 2017 to Jun 2026
- General and administrative expense (US GAAP)47 · Mar 2017 to Jun 2026
- Increase decrease in accounts payable47 · Mar 2017 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets47 · Mar 2017 to Jun 2026
- Investment income interest47 · Mar 2017 to Jun 2026
- Net income loss47 · Mar 2017 to Jun 2026
- Nonoperating income expense47 · Mar 2017 to Jun 2026
- Operating income loss47 · Mar 2017 to Jun 2026
- Research and development expense47 · Mar 2017 to Jun 2026
- Share based compensation47 · Mar 2017 to Jun 2026
- Accrued external research and development expense46 · Dec 2017 to Jun 2026
- Net cash provided by used in operating activities45 · Sep 2017 to Jun 2026
- Accounts payable current44 · Dec 2017 to Jun 2026
- Additional paid in capital common stock44 · Dec 2017 to Jun 2026
- Assets44 · Dec 2017 to Jun 2026
- Assets current44 · Dec 2017 to Jun 2026
- Cash and cash equivalents at carrying value44 · Dec 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect44 · Dec 2017 to Jun 2026
Segment2 concepts · 100 facts · Dec 2018 to Jun 2026
- Operating income loss98 · Dec 2022 to Jun 2026
- Preclinical Research And Clinical Development2 · Dec 2018 to Dec 2019
Segments
100 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments8 members · 100 facts
- Depreciation Expense14 · Dec 2022 to Jun 2026
- Early Stage Preclinical And Discovery Programs14 · Dec 2022 to Jun 2026
- Latestage Development14 · Dec 2022 to Jun 2026
- Other Operational Infrastructure And Advisory Support14 · Dec 2022 to Jun 2026
- Research And Development Personnel Related14 · Dec 2022 to Jun 2026
- Research And Development Software Facilities And Other Strategic Support14 · Dec 2022 to Jun 2026
- Stock- Based Compensation Expense14 · Dec 2022 to Jun 2026
- Preclinical Research And Clinical Development2 · Dec 2018 to Dec 2019
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary99 claims from 9 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary174 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes21 claims from 1 reports · Dec 2025
- Risk factors115 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.